pharmaceut rate downgrad unit state go sg websit
advers still underappreci downgrad hold buy
hold buy
upsid tp
dont disput allergan acquisit mitig impact
near-term gener competit humira shore dividend make
short-term multipl look even attract despit recent sell-off
dcf still signal materi downsid
market
underestim impact subsequ major patent expiri would
prefer narrow pipelin gap combin organ nich
 given manag track record anoth big deal look like
view buy hold
nc chang
chang cut stand-alone pro forma ep estim
realis optimist late-
stage pipelin orilissa/femal health rinvoq/rheumatoid arthriti also expect
biosimilar competit acceler front-end-load eros humira revenu
us despit abbv help comment still believ drug
sourc downsid risk consensu ep forecast blood cancer franchis
valu stock alway base target price tp unweight
averag three-year forward ev/ebita multipl dcf automat
discount stock short- long-term fundament reduc tp
underli earn downgrad compound slower financi de-lever
moreov ev/ebita assign mid-single-digit percentag discount peer
pariti expect top-lin growth sector averag
acknowledg new pro forma tp impli percentag discount
sg global sector coverag univers ep fail see exist
pipelin suppli option requir transform premium grower
input dp estim impli tsr view wane
fundament downgrad rate buy hold
could wrong strongest view realist sourc
upsid risk ebita would abl protect profit
navitoclax phase bone marrow scar deliv sale trajectori line
market leader phase pain manag approv
match success launch categori downsid manag
could engag anoth larg acquisit approach net cash
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor make
invest decis pleas appendix end report analyst certif import
creat via spin-out abbott lab pharma busi humira
treat autoimmun diseas rheumatoid arthriti account abbv
group revenu follow unsuccess attempt acquir shire buy bought
blood cancer specialist pharmacycl bid diversifi away humira
addit inflamm cancer abbv key area therapeut focu
virolog women health neurosci result publish long rang
includ risk adjust non-humira revenu forecast excess
announc intent acquir us special pharma compani allergan
manufactur botox cash stock
product relev invest debat bn
 migrain cosmet
invest debat
reason
gener dividend buyback
via knoll acquisit
via pharmacycl acquisit
jv roch book
sale
hous
licens boehring ingelheim
licens neurocrin
relev propos acquisit allergan
reason
 requir mitig imbruvica patent expiri
mix track record spent acquir us right imbruvica
 spent secur ex-u right stemcentrx
cancer acquir complet written
massiv patent cliff humira imbruvica
stock price volatil sinc
share price rel
previou buy rate base larg belief valuat fail
adequ discount potenti pipelin mitig impact biosimilar competit
humira share price peak januari think happen
increas visibl time impact us biosimilar competit humira due
legal settlement announc septemb
us tax reform drove halv futur underli tax rate
believ two major driver share price under-perform follow
month
increas uncertainti impact biosimilar competit humira europ
began implic might drug us sale trajectori
concern strateg rational acquisit allergan announc
opinion share price ralli strongli low concern
intensifi
investor convict allergan deal increas entri new discount
facial aesthet market hasnt neg impact botox allergan import
increas confid potenti organ pipelin follow manag
comment result present see addendum
downgrad hold buy
model below-averag growth neg surpris
group sale chang sg estim comparison consensu
sg cross asset research/equ bloomberg consensu note allergan consensu forecast use calcul pro forma estim
reduc sale forecast stand-alone pro forma basi tabl
follow reason
humira follow manag comment result call assum
impact us biosimilar competit oner europ
new product launch cut forecast rinvoq rheumatoid arthriti
downgrad mean longer forecast deliv consist premium top-
line growth chart moreov new stand-alone sale
estim consensu believ market optimist
prospect humira blood cancer franchis rinvoq
cut stand-alone pro forma ep forecast tabl
downgrad sale estim describ also previous
bullish abbv abil improv underli profit
downgrad ep estim despit us includ deliveri
unannounc cost save bottom line everi year inclus previous
assum cumul cost cut would deliv period
import stress save increment synergi abbvi
expect allergan acquisit deliv bottom line
non-gaap ep chang top sg estim comparison consensu
valuat look rich
recap alway base target price unweight averag three-year forward
ev/ebita multipl dcf automat take account stock short- long-term
stand-alone rel valuat downgrad premium
mid-single-digit percentag discount growth
sector averag
premium/discount sector
still assum wacc perpetu growth rate
despit recent share price volatil cut target price stand-alone
pro forma see tabl follow reason
downgrad underli estim describ
ev/ebita valuat assum pro forma trade mid-single-digit
percentag discount sg global coverag univers vs pariti stand-alone
previous forecast pro forma top-lin growth consist
sector averag chart
sg cross asset research/equ note growth rate includ allergan
sg cross asset research/equ note growth rate includ allergan
project allergan transact creat valu ev/ebita basi tabl
downgrad underli forecast mean expect take
much longer pro forma repay debt rais financ acquisit
project pro forma entiti net cash vs previous see chart
left moreov downgrad underli estim mean consolid
allergan cash flow vital sustain dividend chart right
sg cross asset research/equ note percentag free
new pro forma tp impli percentag discount sg global sector coverag
univers tabl acknowledg impli stock becom even
outlier vs peer chart right ultim believ pipelin offer
option requir transform premium top-lin grower medium
term moreov experi length pharma product cycl mean
pipelin gap develop take long time discount pharma stock rerat
appropri recent exampl astrazeneca
astrazeneca novarti merck co success buy rate last
three year key reason bullish stock
discrep short-term long-term valuat widest
short-term multipl impli share price expand toward same-year
multipl impli dcf nb pro forma basi dcf
ev/ebita valuat tabl
sinc foundat list jone sustain
djsi world index djsi leader occup health safeti across
biotechnolog pharmaceut industri rank biotechnolog sector
robust environment energi manag system place
manufactur site iso certif iso certif
manag set environment target group sinc compani
reduc scope carbon emiss reduc
hazardous/non-hazard wast gener target
reduct respect vs baselin howev compani lag target
reduct absolut water withdraw increas vs
target reduct compani plan spend capital-expenditure
opex pollut control
board structur board director bod consist three class elect
three-year term role ceo chairman board held person
richard gonzalez lead independ director chosen bod respons ensur
appropri level oversight independ respons appli board
decis thu act best interest stockhold forty-f percent
member board women characteris ethnic divers
capit structur end compani common share
outstand carri one vote right exclud share
issu help financ acquisit allergan
esg govern bod public polici committe overse corpor
access medicin compani provid free medic patient us
sign third agreement medicin patent mpp grant royalty-fre
licens hepat drug enabl world organis recognis
gener manufactur produc lower-cost gener version product
low- middle-incom countri
becam signatori london declar neglect tropic diseas
group donat hour paid work time conduct research neglect
tropic diseas includ malaria tuberculosi
capit manag rank fortun best compani
work employe survey indic engag rate vs benchmark
rate promot gender equal divers within organis
femal employe account workforc top manag posit
thirty-on percent us employe member underrepres popul
could wrong
navitoclax investig drug candid current phase combin jakafi
treatment relapsed/refractori myelofibrosi r/r mf condit rare form
blood cancer preval patient us reduc bone marrow
abil produc normal red white blood cell drug invent in-hous
previous develop jointli roch sever solid blood cancer indic
collabor end
navitoclax oral small molecul inhibitor b-cell leukaemia famili protein
select bind three bcl-xl bcl-w frequent overexpress
wide varieti solid blood cancer protein link tumour drug resist
prevent cancer cell die navitoclax inhibit protein therebi promot
death tumour cell overexpress
navitoclax broader mechan action abbv venclexta sale
approv use chronic lymphocyt leukaemia cll acut myeloid leukaemia aml
target venclexta effect patient express
common howev small subset patient tumour growth bcl-xl
depend navitoclax thought effect
phase singl arm result navitoclax present demonstr
navitoclax combin jakafi well toler clinic meaning spleen
respons improv total symptom score tss produc reduct bone marrow
fibrosi among patient primari secondari mf phase trial r/r
treatment nave patient combin jakafi expect commenc year
expect submit drug fda secur approv
sg cross asset research/equ evalu pharma note combin sale novarti
forecast risk adjust sale navitoclax howev drug achiev
revenu year similar trajectori jakafi chart assum
contribut margin would mid-singl digit percentag upsid
antibodi drug conjug adc complex molecul consist antibodi protein
carrier link small molecul payload develop
treatment rheumatoid arthriti ra combin anti-tumour necrosi factor tnf
monoclon antibodi steroid diagram
present stand-alone anti-tnf drug steroid use combin treat autoimmun
diseas like ra inflammatori bowel diseas ibd psoriasi howev dose
latter limit due risk system side effect osteoporosi women
potenti valu proposit steroid payload deliv
accur inflam tissu thu minimis advers impact healthi tissu
current run double-blind double-dummi phase trial compar
humira due complet
ra autoimmun diseas characteris pain swell stiff joint
global preval rate approxim affect million adult us
estim ra drug sale exceed cure ra avail
therapi reduc inflamm prevent joint organ damag current treatment
paradigm ra follow
non-steroid anti-inflammatori drug nsaid use manag pain inflamm
alter progress ra
disease-modifi antirheumat drug dmard temper immun system attack
bodi thu slow progress ra
biolog blocker like humira target part immun system modul
inflamm ra case effect
structur
mechan action
anti-tnf target inflam tissu
anti-tnf demonstr compar efficaci high dose
steroid without side effect preclin studi
current carri sale estim model drug
still phase howev drug achiev sale similar ramp-up
merck co vioxx assum contribut margin would
mid-single-digit-percentag upsid pro forma group ebita estim
forecast abbv pro forma margin contract project
below-averag sale growth chart import stress project trend
despit includ guid synergi allergan acquisit addit
increment unannounc annual save everi year thereaft
wrong deliv profit line
would high-singl digit percentag upsid pro forma non-gaap ebita forecast
year
previous discuss forecast pro forma basi abbvi sale growth
quit volatil chart right thing current stand
believ organ pipelin abl mitig impact imbruvica patent expiri
forecast compani financi flexibl larg
restor chart left year forecast gener pro forma ebitda
henc given manag decis middl last year acquir allergan
believ risk similar size transact second half decad
shouldnt ignor moreov experi last year suggest
transact size seldom creat sharehold valu
sg cross asset research/equ note growth rate includ allergan
product sold
equival
total liabil equiti
depreci amortis
chang work capit
flow oper activ
purchas secur net
flow invest activ
net chang debt
purchas treasuri stock
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
end year
chang wc
tabl model impact central scenario posit
neg take relev product current portfolio late-stag
pipelin help us calibr magnitud risk compani face go
forward use ebit analysi given long product cycl
pharmaceut industri forecast upsid risk ebit downsid
sale varianc sourc upsid downsid
ebit varianc sourc upsid downsid
driver drag sale
 revenuedeclin revenu sale
investig small molecul develop treatment
rheumatoid arthriti ra system lupu erythematosu sle drug combin abbv-
rinvoq select irrevers inhibitor bruton tyrosin kinas btk
current phase ra sle rinvoq select inhibitor
fda approv treatment sever ra
current btk inhibitor imbruvica calquenc astrazeneca
approv treatment sever blood cancer drug also shown
promis result certain preclin earli clinic trial treatment autoimmun
diseas jak inhibitor alreadi approv therapi treatment ra rinvoq xeljanz
olumi sle olumi
current run two phase clinic trial ra compar safeti efficaci
vs vs placebo data studi due releas
compani also run phase trial sle compar
rinvoq trial expect readout
sle like ra autoimmun diseas bodi immun system attack tissu
caus inflamm tissu damag impact joint skin brain lung kidney
blood vessel accord centr diseas control cdc preval definit sle
patient definit probabl sle preval patient usa
sle characteris period flare remiss diseas larg
treat off-label immunosuppress howev fda approv first new drug
treatment sle year gsk benlysta sale follow
public success phase trial astrazeneca file anifrolumab
fda treatment diseas
biolog develop treatment ulcer coliti antagonist
 tumor necrosi factor tnf receptor superfamili member express immun
non-immun cell
ulcer coliti uc type inflammatori bowel diseas ibd characteris
irrit inflamm ulcer sore innermost line larg intestin colon
rectum sever debilit condit hamper qualiti life
uc cure avail treatment tri reduc symptom diseas
case long-term remiss also achiev treatment option includ acid
corticosteroid immunosuppress biolog per cdc million peopl usa
diagnos ibd includ crohn diseas ulcer coliti accord evalu
pharma annual ibd market worth around
phase proof concept poc data expect relas
phase trial success plan launch phase trial next year
nb also run phase trial crohn diseas anoth type ibd
program discontinu last year
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
america corp
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report justin smith
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
straight averag sotp base averag ev/ebita multipl dcf wacc termin growth automat
discount stock short- long-term fundament
upsid greatest view realist sourc upsid risk ebita would abl protect
profit navitoclax phase bone marrow scar deliv sale trajectori line market leader
phase pain manag approv match success launch categori
downsid manag could engag anoth larg acquisit approach net cash
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
equiti rate dispers relationship
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin use
creat financi product includ indic inform provid basi user assum entir risk
use made inform affili third parti involv relat comput compil inform
herebi expressli disclaim warranti origin accuraci complet merchant fit particular purpos
respect inform without limit forego event shall affili third parti involv
relat comput compil inform liabil damag kind morgan stanley capit
index servic mark affili similar languag may provid approv
advanc
report contain contribut research team esg numer rate highest score base
four step rate methodolog includ identifi materi esg factor associ weight sector ii provid key
perform indic compani evalu iii calcul quantit esg rate base sustainalyt data combin sg equiti
esg rate identifi top pick esg rate group three equal tier tier tier contain compani
highest esg numer score esg numer rate consid fundament rate kind complet
separ sg equiti credit rate
coveredco w/ bank relationship
sg partner sustainalyt independ provid esg data research support servic gather esg data use
public sustainalyt affili sg sg warrant complet accuraci sustainalyt analysi data
